

Clinical Trial Protocol

Iranian Registry of Clinical Trials

28 May 2026

High dose atorvastatin effects on cardiac biomarkers (24 hours after CABG): 80 mg vs 40 mg

Protocol summary

Summary

In this study we aim to divide patients candidate for CABG at Tehran Heart Center in two randomized groups: patients of group 1 will received 80 mg atorvastatin daily patients of group 2 will received 40 mg atorvastatin daily (Atorvastatin will begin since 5 days before surgeries.) we will compare 8 and 24 hours post-CABG CKMB and high sensitive cTnT and other short-term outcomes (AF incidence rates, ICU admission hours, CVA/TIA, and etc) between the two groups. Intervention (atorvastatin use) duration: 5 days

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT2016112231024N1**
Registration date: **2017-05-06, 1396/02/16**
Registration timing: **registered_while_recruiting**

Last update:

Update count: **0**

Registration date

2017-05-06, 1396/02/16

Registrant information

Name

Arash Shekari

Name of organization / entity

Tehran Heart Center / Tehran University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 21 8802 9600

Email address

a-shekari@razi.tums.ac.ir

Recruitment status

Recruitment complete

Funding source

Tehran Heart Center

Expected recruitment start date

2017-05-01, 1396/02/11

Expected recruitment end date

2017-06-01, 1396/03/11

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

High dose atorvastatin effects on cardiac biomarkers (24 hours after CABG): 80 mg vs 40 mg

Public title

High dose atorvastatin effects on cardiac biomarkers (24 hours after CABG)

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criterion: admission for CABG in Tehran Heart Center. Exclusion criteria: other heart surgeries; COPD; emergent surgeries; liver insufficiency; renal dysfunction (Cr > 1.5); MI (myocardial infarction) since recent 6 weeks; age > 75 years old.

Age

To 75 years old

Gender

Both

Phase

N/A

Groups that have been masked

No information

Sample size

Target sample size: **118**

Randomization (investigator's opinion)

Randomized
Randomization description
Blinding (investigator's opinion)
Double blinded
Blinding description
Placebo
Not used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee
Tehran Heart Center ethics committe
Street address
Tehran Heart Center, north kargar street, jalal al
ahmad cross, Tehran, Iran
City
Tehran
Postal code
Approval date
2017-04-30, 1396/02/10
Ethics committee reference number
IR.TUMS.MEDICINE.REC.1396.2174

Health conditions studied

1

Description of health condition studied

Coronary artery disease
ICD-10 code
I25.1
ICD-10 code description
Atherosclerotic heart disease

Primary outcomes

1

Description

CKMB and high sensitive cTnT 24 hours after CABG
Timepoint
24 hours before and 8 and 24 hours after CABG
Method of measurement
CKMB and high sensitive cTnT (ELIZA)

Secondary outcomes

empty

Intervention groups

1

Description

patients of group 1 will recieved 80 mg atorvastatin daily
for 5 days

Category

Treatment - Drugs

2

Description

patients of group 2 will recieve 40 mg atorvastatin daily
for 5 days

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center
Tehran Heart Center
Full name of responsible person
arash shekari
Street address
Tehran Heart Center, North Kargar street, Jalal al
Ahmad cross
City
Tehran

Sponsors / Funding sources

1

Sponsor

Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Vice Chancellor for Research (Dr masud Yunesian)
Street address
Vice Chancellor for Research, 6th floor, Tehran
University of Medical Sciences, Qods street,
Keshavarz Avenue
City
tehran

Grant name

طرح به عنوان پایان نامه برای اخذ دکترای تخصصی قلب و عروق
تصویب شده است

Grant code / Reference number

**Is the source of funding the same sponsor
organization/entity?**
Yes

Title of funding source

Tehran University of Medical Sciences

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

empty

Person responsible for general inquiries

Contact

Name of organization / entity

Tehran Heart Center

Full name of responsible person

Arash Shekari

Position

MD, resident of cardiology

Other areas of specialty/work

Street address

Tehran Heart Center, North Kargar street, Jalal al Ahmad cross

City

Tehran

Postal code

Phone

+98 21 8802 9600

Fax

Email

a-shekari@razi.tums.ac.ir

Web page address

Phone

+98 21 8802 9600

Fax

Email

a-shekari@razi.tums.ac.ir

Web page address

Person responsible for updating data

Contact

Name of organization / entity

Tehran Heart Center

Full name of responsible person

Arash Shekari

Position

MD, resident of cardiology

Other areas of specialty/work

Street address

Tehran Heart Center, North Kargar street, Jalal al Ahmad cross

City

Tehran

Postal code

Phone

+98 21 8802 9600

Fax

Email

a-shekari@razi.tums.ac.ir

Web page address

Person responsible for scientific inquiries

Contact

Name of organization / entity

Tehran Heart Center

Full name of responsible person

Arash Shekari

Position

MD, resident of cardiology

Other areas of specialty/work

Street address

Tehran Heart Center, North Kargar street, Jalal al Ahmad cross

City

Tehran

Postal code

Sharing plan

Deidentified Individual Participant Data Set (IPD)

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty